We describe a gas-chromatographic method for p-chlorophenoxyisobutyric acid (I) the active metabolite of dofibrate. The drug and internal standards are separated from either serum or saliva by a double extraction procedure and converted to the corresponding butyl esters by reaction with iodobutane in a mixture of methanol and N,N-dimethylacetamide containing tetramethylammonium hydroxide. Within-run CV of this assay at a serum I concentration of 79.2 mg/liter was 2.3% and at a salivary I concentration of 2.5 mg/liter was 2.1 % -Precision during four months of the serum and salivary assays at these concentrations was 4.1 % and 6.2%, respectively. The mean serum concentration of 1(12 h after dose) in patients receiving the drug at an average dose of 28.0 mg/kg per day was 109.6 mg/liter. Serum and salivary concentrations of I as determined by our procedure were used to calculate the unbound fraction of drug in human serum. Such measurements can be used to monitor therapy in patients with renal disease, where drug toxicity may arise from high concentrations of unbound I.
hydrolysis
of this compound to p -chlorophenol, was developed by Barrett and Thorp (4 ); however, it has limited application to clinical specimens because other acidic drugs in serum may interfere with the ultraviolet absorption of the derived p -chlorophenol. Several gas-chromatographic methods for CPIB have also been described (5-8). However, one of these procedures (5) requires a preliminary thin-layer chromatographic separation of CPIB from fatty acids in plasma, and in all the others diazomethane is used to prepare the methylated derivative (6-8). Because of these limitations, we did not consider these procedures appropriate for routine use in our Therapeutic Drug Monitoring
Laboratory. The gas-chromatographic method of Gu-.
gler et al. (9) avoids the potential hazards of diazomethane by esterifying CPIB with dimethylsulfate in alcoholic potassium carbonate. These workers utilized clofibrate as their internal standard, and we were concerned that some individuals might, because of disease or the presence of other drugs, have significant amounts of the parent compound in their serum. Recently Karmen and Haut (10) described a method for CPIB in which they used a gas chromatograph equipped with flame-ionization detector selectively sensitive to halogen. When serum samples, extracted and derivatized according to their procedure, were analyzed with a conventional hydrogen flame ionization detector they observed large quantities of the methyl esters of other fatty acids, which far exceeded the amounts of CPIB present and made quantitation difficult. Bruderlein et al. (11) reported a gas-chromatographic procedure for CPIB based on flame-ionization detection of the methyl ester of this drug, which was prepared by reaction with methanolic HC1 at room temperature.
This method was precise and results correlated well with those from the ultraviolet spectrophotometric procedure when the latter results were corrected for the nonspecific background absorbance of control sera.
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Greeley described a procedure for the alkylation of organic acids in which the tetramethylammonium salt of the acid reacts with an excess of primary alkyl iodide in methanolic N,N-dimethylacetamide (13) . This reaction is mild, rapid, and complete and has been used in our laboratory for the alkylation of theophylline (13) 
Materials and Methods

Chemicals and Comparison Materials
Reagents
Prepare stock solutions (1 mg/ml) of CPIB, p-chlorophenoxyacetic acid (CPAA), and 3-(p -chlorophenoxy)propionic acid (CPPA) by dissolving 111 mg of the sodium salt of p -chlorophenoxyisobutyric acid and 100 mg of each of the other compounds in 100 ml of methanol. Prepare a working solution of CPIB (100 sg/ml) by diluting 10 ml of the stock solution to 100 ml with methanol and prepare a working solution containing both internal standards, CPAA (150 ig/ml) and CPPA (150 zg/ml), by combining 15 ml of each stock solution and diluting to 100 ml with methanol. Prepare 7.4 mol/liter NH4OH in methanol freshly for each run by diluting concentrated NH4OH with an equal volume of methanol. 
Gas-Liquid Chromatography
We used a Model 5711A dual-column gas chromatograph equipped with flame ionization detectors (Hewlett-Packard, Avondale, Pa. 14311). The glass columns (120 cm X 2 mm Ld.), configuration 5 for on-column injection, were packed with 3% OV-17 on 100/120 Gas Chrom Q (Applied Science Laboratories, Inc., State College, Pa. 16801). Septa were type HT-9 (Applied Science Laboratories), high temperature, low bleed.
The injection-port temperature was 250 #{176}C, detector temperature 300 #{176}C; the oven temperature was programmed from 130 #{176}C to 240 #{176}C at a rate of 16 #{176}C/min. The flow rate for the carrier gas, N2, was set at 50 ml/ mm; the air flow rate was 250 ml/min; the H2 flow rate was 40 ml/mmn; and the chart speed was 13 mm/mm.
Results and Discussion
In preliminary studies, we prepared a series of Nalkyl esters of CPIB according to the procedure of Greeley (12) . Of the compounds studied, the N-butyl ester exhibited a chromatographic peak that was not subject to interference by substances normally encountered in human serum or saliva. Accordingly, we selected this derivative for use in our routine procedure for CPIB. CPAA and CPPA were used as internal standards because of their chemical similarity to CPIB. These compounds are all highly volatile and care must be exercised during the evaporation steps in our procedure, because it has been demonstrated by Karmen and Haut that they are not always lost in equal proportions Recovery of CPIB and of the two internal standards from serum and saliva was determined in the following manner: 25 l of drug-free serum and 500 l of drug-free saliva were added to separate tubes containing 80 g of CPIB, CPAA, and CPPA. These samples were extracted as described above; however, all volume transfers were quantitated. A second, nonextracted standard containing 80 tg of each compound was prepared. All samples were derivatized as described in the Methods section and exactly 2.5 tl of each sample was chromatographed. The peak heights of the extracted samples were then corrected for solvent transfers. Absolute recoveries of the compounds were calculated by comparison of the ratio of the corrected peak height of the extracted samples to that of the nonextracted standard.
The absolute recoveries of CPIB, CPAA, and CPPA from serum were 89.1%, 95.9%, and 99.8%, respectively, and from saliva were 91.5%, 90.9%, and 95.3%, respectively.
The within-run coefficient of variation (CV) of our assay at a serum CPIB concentration of 79.2 mg/liter -was 2.3% (n = 10); at a saliva CPIB concentration of 2.46 mg/liter it was 2.1% (n = 10). During four months, the between-run precision of this assay at these concentrations was 4.1% for serum (n = 20) and 6.2% for saliva (n = 20).
Although separate standard curves for serum and saliva were included with each analytical run from which our precision data were derived, we subsequently determined that the relative peak-height ratios of the salivary standards did not differ significantly from those of the serum standards. Therefore, for routine determinations serum-based standards were used for the analysis of CPIB in both serum and saliva.
We compared our gas-chromatographic procedure for X .,X100
[serum] 1 + 10pH saliva-pita They also measured amobarbital binding to plasma proteins in these subjects directly by equilibrium dialysis and compared these results to values estimated with this formula. The calculated and observed values for the unbound fraction of amobarbital were in excellent agreement.
CPIB is an acid (pKa = 3.1) and is extensively bound to human albumin. At usual therapeutic concentrations in individuals with normal renal function, the extent of binding of CPIB, as determined by equilibrium dialysis, was about 95-97% (2, 9). In contrast, 80 to 93% of the drug was bound to albumin in patients with the nephrotic syndrome (2, 9). It has been claimed that the higher concentrations of unbound CPIB in these patients are responsible for its toxic effects, which include muscle pain, stiffness, weakness, and general malaise (3). We used our gas-chromatographic method to indirectly estimate the extent of binding of CPIB to serum albumin. Serum and salivary concentrations of the drug were determined and the unbound fraction was calculated. In an individual with normal renal function, the bound fraction of CPIB was estimated to be 96.4%. In an individual with severe renal insufficiency (creatinine clearance less than 5 ml/min) the bound fraction was 88.8%. These values are in excellent agreement with those reported in the literature.
The simultaneous determination of serum and salivary CPIB with our gaschromatographic method can therefore be used to ascertain and avoid toxicity caused by high concentrations of unbound drug.
